2025
Lipid Peroxidation and Glutathione Levels Among People Living With HIV Co‐infected With Human Coronaviruses in Ghana
Amegashie E, Kwayisi‐Darkwah C, Adusei‐Poku M, Sikeola R, Ativi L, Ahene A, Atampugbire G, Tagoe E, Paintsil E, Torpey K, Quaye O. Lipid Peroxidation and Glutathione Levels Among People Living With HIV Co‐infected With Human Coronaviruses in Ghana. Journal Of Medical Virology 2025, 97: e70301. PMID: 40110873, DOI: 10.1002/jmv.70301.Peer-Reviewed Original ResearchMeSH KeywordsAdultCoinfectionCoronavirus InfectionsCross-Sectional StudiesCyclopropanesDideoxyadenosineDideoxynucleosidesFemaleGhanaGlutathioneHeterocyclic Compounds, 3-RingHIV InfectionsHumansLipid PeroxidationMaleMalondialdehydeMiddle AgedOxazinesOxidative StressPiperazinesProspective StudiesPyridonesYoung AdultConceptsHuman immunodeficiency virusHuman immunodeficiency virus co-infectionCo-infectionGSH levelsART-experienced individualsPLWH co-infectedHuman coronavirusesHIV co-infectionHIV-negative individualsMalondialdehyde levelsOxidative stressOxidative stress markersIncreased MDA levelsCross-sectional studyOro-pharyngeal swabsImmunodeficiency virusGhanaian patientsMono-infectionReduced GSH levelsTreatment strategiesPlasma samplesDisease severityMDA levelsStress markersTailored monitoringApixaban to Prevent Covert Infarcts After Cryptogenic Stroke in Patients With Atrial Cardiopathy
Lansberg M, Wintermark M, Chen H, Howard G, Cassarly C, Pauls Q, Kemp S, Harris T, Krishnaiah B, Stanton R, Lyerly M, Miller B, Smith E, Tirschwell D, Sheth K, Kamel H, Longstreth W, Elkind M, Broderick J, Lazar R. Apixaban to Prevent Covert Infarcts After Cryptogenic Stroke in Patients With Atrial Cardiopathy. JAMA Neurology 2025, 82: 220-227. PMID: 39869342, PMCID: PMC11773411, DOI: 10.1001/jamaneurol.2024.4838.Peer-Reviewed Original ResearchConceptsCovert infarctsResearch magnetic resonance imagingCompletion of participationParticipant completionAtrial cardiopathyMain OutcomesParent studyRandomized clinical trialsPrimary outcomeFollow-up magnetic resonance imagingMagnetic resonance imagingParticipantsFollow-up periodRecurrent strokeStrokeIschemic strokeFollow-upBaseline characteristicsAncillary studiesCryptogenic strokeBaselineInsufficient qualityPreventionInfarctionIQRInvestigational gene expression inhibitors for the treatment of idiopathic pulmonary fibrosis
Spagnolo P, Tonelli R, Mura M, Reisman W, Sotiropoulou V, Tzouvelekis A. Investigational gene expression inhibitors for the treatment of idiopathic pulmonary fibrosis. Expert Opinion On Investigational Drugs 2025, 34: 61-80. PMID: 39916340, DOI: 10.1080/13543784.2025.2462592.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisGene therapyPulmonary fibrosisAssociated with tolerability issuesProgressive fibrosing interstitial lung diseaseEfficacy of gene therapyApplication of gene therapyTreatment of idiopathic pulmonary fibrosisLong-term clinical dataFibrosing interstitial lung diseaseFirst-line therapyImproved vector designInterstitial lung diseaseMitigate off-target effectsTolerated treatmentDismal prognosisClinical dataLung diseaseClinical studiesAssociated with poor qualityProfibrotic pathwaysTarget cellsTherapyFibrosisOff-target effects
2024
Effectiveness of dolutegravir-based regimens compared to raltegravir-, elvitegravir-, bictegravir, and darunavir-based regimens among older adults with HIV in the Veterans Aging Cohort Study (VACS)
Yan L, Henegar C, Marconi V, Gordon K, Hicks C, Vannappagari V, Justice A, Aslan M. Effectiveness of dolutegravir-based regimens compared to raltegravir-, elvitegravir-, bictegravir, and darunavir-based regimens among older adults with HIV in the Veterans Aging Cohort Study (VACS). AIDS Research And Therapy 2024, 21: 96. PMID: 39709467, PMCID: PMC11662819, DOI: 10.1186/s12981-024-00681-w.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmidesAnti-HIV AgentsCohort StudiesDarunavirDrug Therapy, CombinationFemaleHeterocyclic Compounds, 3-RingHeterocyclic Compounds, 4 or More RingsHIV InfectionsHIV Integrase InhibitorsHumansMaleMiddle AgedOxazinesPiperazinesPyridazinesPyridonesQuinolonesRaltegravir PotassiumTreatment OutcomeVeteransViral LoadConceptsVeterans Aging Cohort StudyRAL-based regimenAntiretroviral therapyAging Cohort StudyCohort studyOdds of virologic suppressionIntegrase strand transfer inhibitorsDarunavir-based regimensDolutegravir-based regimensDTG-based regimensAntiretroviral therapy experienceHuman immunodeficiency virusDTG-based regimenInverse probability of treatment weightingStrand transfer inhibitorsBackgroundReal-world dataProbability of treatment weightingMethodsThis cohort studyVirologic suppressionVirological failureVirological effectImmunodeficiency virusDarunavir/ritonavirClinical outcomesRegimen initiationEffect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS
Fanaroff A, Vora A, Wojdyla D, Mehran R, Granger C, Goodman S, Aronson R, Windecker S, Alexander J, Lopes R. Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS. American Heart Journal 2024, 280: 60-69. PMID: 39557109, DOI: 10.1016/j.ahj.2024.11.005.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeTime-to-event analysisAtrial fibrillationCoronary syndromeClinical trialsEffect of antithrombotic therapyVitamin K antagonistsProportion of patientsRobust variance estimationRandomized clinical trialsClinical trial endpointsPercutaneous coronary interventionK antagonistsAntithrombotic therapyPoisson regressionTreatment armsFollow-upIschemic eventsPlaceboRate ratiosAntithrombotic agentsTrial endpointsWarfarinCoronary interventionIntervention methodsDirect oral anticoagulant approvals by four major regulatory agencies: a cross-sectional analysis of premarket and postmarket evidence
Mooghali M, Zhou T, Ross J. Direct oral anticoagulant approvals by four major regulatory agencies: a cross-sectional analysis of premarket and postmarket evidence. BMJ Open 2024, 14: e090376. PMID: 39461853, PMCID: PMC11529451, DOI: 10.1136/bmjopen-2024-090376.Peer-Reviewed Original ResearchConceptsPhase 2 trialPhase 3 trialBox warningAtrial fibrillation patientsPostmarketing evidenceEvidence of safetyOral anticoagulantsFibrillation patientsPostmarketing studiesCross-sectional analysisDegree of concordanceStroke preventionStudy requirementsPostmarketingEfficacy evidenceRegulatory agenciesDrugPostmarketing requirementsInterpretation of resultsEfficacyHealth CanadaSample sizeSafety evidenceConcordanceEndpointTranscriptional repression by HDAC3 mediates T cell exclusion from Kras mutant lung tumors
McGuire C, Meehan A, Couser E, Bull L, Minor A, Kuhlmann-Hogan A, Kaech S, Shaw R, Eichner L. Transcriptional repression by HDAC3 mediates T cell exclusion from Kras mutant lung tumors. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2317694121. PMID: 39388266, PMCID: PMC11494357, DOI: 10.1073/pnas.2317694121.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBenzamidesCell Line, TumorChemokine CXCL10Gene Expression Regulation, NeoplasticHistone Deacetylase InhibitorsHistone DeacetylasesHumansLung NeoplasmsMiceMutationProto-Oncogene Proteins p21(ras)PyridinesPyridonesPyrimidinonesT-LymphocytesTranscription, GeneticTumor MicroenvironmentConceptsT cell recruitmentLung tumorsHistone deacetylase 3Enhanced T cell recruitmentCombined treatmentLung tumors in vivoGenetically engineered mouse modelsT cell exclusionInhibition of histone deacetylase 3Tumor immune microenvironmentTumor growth controlKRAS mutant lung tumorsTumors in vivoLung cancer cellsImmune microenvironmentT cellsTissue-specific fashionMouse modelPathway inhibitorTumorPharmacological inhibitionCancer cellsFunction in vivoTranscriptional regulationTranscriptional repressionBexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial
Lancaster L, Cottin V, Ramaswamy M, Wuyts W, Jenkins R, Scholand M, Kreuter M, Valenzuela C, Ryerson C, Goldin J, Kim G, Jurek M, Decaris M, Clark A, Turner S, Barnes C, Achneck H, Cosgrove G, Lefebvre É, Flaherty K, Baratz D, Ettinger N, Layish D, Epstein M, Veeraraghavan S, Golden J, Ramaswamy M, Bascom R, Lancaster L, Scholand M, Case A, Zaman T, Betensley A, Antin-Ozerkis D, Montessi S, Fernandez E, Boente R, Sager J, Hunninghake G, Gibson K, Srour N, Dhar A, Wuyts W, Wielders P, Veltkamp M, Mostard R, Janssen R, Noordegraaf A, Glaspole I, Corte T, Beckert L, Brockway B, Veale A, Richeldi L, Harari S. Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial. American Journal Of Respiratory And Critical Care Medicine 2024, 210: 424-434. PMID: 38843105, PMCID: PMC11351797, DOI: 10.1164/rccm.202403-0636oc.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsQuantitative lung fibrosisIdiopathic pulmonary fibrosisPulmonary fibrosisRates of treatment-emergent adverse eventsIncidence of treatment-emergent adverse eventsClinical trialsTreatment of idiopathic pulmonary fibrosisExploratory efficacy endpointsImpaired quality of lifeFibrosis-related biomarkersDose cohortsBackground therapyPlacebo groupTolerability profileOnce-dailyEfficacy endpointPrimary endpointProgressive diseaseExertional dyspneaFVC declineFibrosis biomarkersAdverse eventsIPF therapyLung fibrosisONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma
Arrillaga-Romany I, Gardner S, Odia Y, Aguilera D, Allen J, Batchelor T, Butowski N, Chen C, Cloughesy T, Cluster A, de Groot J, Dixit K, Graber J, Haggiagi A, Harrison R, Kheradpour A, Kilburn L, Kurz S, Lu G, MacDonald T, Mehta M, Melemed A, Nghiemphu P, Ramage S, Shonka N, Sumrall A, Tarapore R, Taylor L, Umemura Y, Wen P. ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma. Journal Of Clinical Oncology 2024, 42: 1542-1552. PMID: 38335473, PMCID: PMC11095894, DOI: 10.1200/jco.23.01134.Peer-Reviewed Original ResearchConceptsH3 K27M-mutant diffuse midline gliomaDiffuse midline gliomaDuration of responseTime to responseHigh-grade gliomasLow-grade gliomasMidline gliomaMedian duration of responseMedian time to responseTreatment-emergent adverse eventsEnd pointsBlinded independent central reviewCorticosteroid dose reductionIndependent central reviewSecondary end pointsClinically meaningful efficacyRadiographic end pointsSpinal tumorsDose reductionDismal prognosisCentral reviewPerformance scoresCorticosteroid responseResponse assessmentAdverse eventsCombined BET and MEK Inhibition synergistically suppresses melanoma by targeting YAP1
Hu R, Hou H, Li Y, Zhang M, Li X, Chen Y, Guo Y, Sun H, Zhao S, Liao M, Cao D, Yan Q, Chen X, Yin M. Combined BET and MEK Inhibition synergistically suppresses melanoma by targeting YAP1. Theranostics 2024, 14: 593-607. PMID: 38169595, PMCID: PMC10758063, DOI: 10.7150/thno.85437.Peer-Reviewed Original ResearchConceptsMEK inhibitor resistanceMEK inhibitor trametinibTrametinib treatmentInhibitor resistanceInhibitor trametinibMelanoma patientsYAP1 expressionMEK inhibitionBRAF-mutant melanoma patientsResistance to MEK inhibitionYAP1 inhibitionResistance to trametinibMelanoma growth <i>inInhibition of BRD4Trametinib resistanceAntitumor effectMelanoma growthTrametinibNHWD-870YAP1 inhibitorDrug resistanceMelanomaMelanoma samplesMelanoma cellsBRD4 depletion
2023
Identifying treatment heterogeneity in atrial fibrillation using a novel causal machine learning method
Ngufor C, Yao X, Inselman J, Ross J, Dhruva S, Graham D, Lee J, Siontis K, Desai N, Polley E, Shah N, Noseworthy P, MN; New Haven C. Identifying treatment heterogeneity in atrial fibrillation using a novel causal machine learning method. American Heart Journal 2023, 260: 124-140. PMID: 36893934, PMCID: PMC10615250, DOI: 10.1016/j.ahj.2023.02.015.Peer-Reviewed Original ResearchConceptsOral anticoagulantsAtrial fibrillationPatient subgroupsComposite outcomeIschemic strokeEffect of OACsLifelong oral anticoagulationNonvitamin K antagonistNew oral anticoagulantsNonvalvular atrial fibrillationPrimary composite outcomeGlomerular filtration rateFuture prospective studiesOptumLabs Data WarehousePopulation-level effectivenessOAC useOral anticoagulationVASc scoreCause mortalityK antagonistsPrimary endpointWarfarin usersRenal functionAF patientsEntire cohortCombined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial
Tian J, Chen J, Chao S, Pelka K, Giannakis M, Hess J, Burke K, Jorgji V, Sindurakar P, Braverman J, Mehta A, Oka T, Huang M, Lieb D, Spurrell M, Allen J, Abrams T, Clark J, Enzinger A, Enzinger P, Klempner S, McCleary N, Meyerhardt J, Ryan D, Yurgelun M, Kanter K, Van Seventer E, Baiev I, Chi G, Jarnagin J, Bradford W, Wong E, Michel A, Fetter I, Siravegna G, Gemma A, Sharpe A, Demehri S, Leary R, Campbell C, Yilmaz O, Getz G, Parikh A, Hacohen N, Corcoran R. Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial. Nature Medicine 2023, 29: 458-466. PMID: 36702949, PMCID: PMC9941044, DOI: 10.1038/s41591-022-02181-8.Peer-Reviewed Original ResearchConceptsPrimary end pointColorectal cancerResponse rateEnd pointPD-1Immune responseSingle-arm phase 2 clinical trialMAPK inhibitionMEK inhibitionPhase 2 clinical trialTreatment tumor biopsiesDisease control rateSecondary end pointsPhase 2 trialProgression-free survivalBetter clinical outcomesDuration of responseOverall response rateTumor immune responseFurther clinical evaluationTumor cell-intrinsic mechanismsMAPK pathway inhibitionPatient-derived organoidsCell-intrinsic mechanismsOverall survival
2022
Apixaban at Apex? Aligning Drug Pricing With Value in Cancer-Associated Thrombosis.
Ito S, Goshua G. Apixaban at Apex? Aligning Drug Pricing With Value in Cancer-Associated Thrombosis. Annals Of Internal Medicine 2022, 176: 125-126. PMID: 36571840, DOI: 10.7326/m22-3404.Peer-Reviewed Original ResearchGenetic Evolution of Avian Influenza A (H9N2) Viruses Isolated from Domestic Poultry in Uganda Reveals Evidence of Mammalian Host Adaptation, Increased Virulence and Reduced Sensitivity to Baloxavir
Atim G, Tugume T, Ukuli Q, Erima B, Mubiru A, Kibuuka H, Mworozi E, McKenzie P, Turner J, Walker D, Jeevan T, Webster R, Jones J, Webby R, Ducatez M, Wabwire-Mangen F, Byarugaba D. Genetic Evolution of Avian Influenza A (H9N2) Viruses Isolated from Domestic Poultry in Uganda Reveals Evidence of Mammalian Host Adaptation, Increased Virulence and Reduced Sensitivity to Baloxavir. Viruses 2022, 14: 2074. PMID: 36146881, PMCID: PMC9505320, DOI: 10.3390/v14092074.Peer-Reviewed Original ResearchConceptsMammalian host adaptationHost adaptationInfluenza A virusLive bird marketsEvolution of H9N2 virusesGenetic evolution of H9N2 virusesH9N2 virusesGenetic evolutionIllumina MiSeq platformSequencing data analysisA virusGenome sequenceBird marketsAvian influenza A virusesNucleotide substitutionsMiSeq platformPromote drug resistancePoor biosecurity practicesIncreased virulenceContemporary isolatesH9N2 isolatesAvian influenza ACloacal samplesAnti-influenza drugsBaloxavir acidPhase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
Johnson B, Haymaker C, Parra E, Soto L, Wang X, Thomas J, Dasari A, Morris V, Raghav K, Vilar E, Kee B, Eng C, Parseghian C, Wolff R, Lee Y, Lorenzini D, Laberiano-Fernandez C, Verma A, Lang W, Wistuba I, Futreal A, Kopetz S, Overman M. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Journal For ImmunoTherapy Of Cancer 2022, 10: e005332. PMID: 36007963, PMCID: PMC9422817, DOI: 10.1136/jitc-2022-005332.Peer-Reviewed Original ResearchConceptsMicrosatellite stable (MSS) metastatic colorectal cancerTreatment-related adverse eventsMetastatic colorectal cancerResponse rateStable diseasePartial responsePD-1Lung metastasesColorectal cancerT cellsCommon treatment-related adverse eventsMedian age 48 yearsMedian progression-free survivalTumor microenvironmentCombination of trametinibPhase II studyPhase II trialProgression-free survivalCD8 T cellsImmune checkpoint blockadeT cell infiltrationImmune tumor microenvironmentOverall response rateAge 48 yearsComparison of baselineApixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke
Bahit M, Vora A, Li Z, Wojdyla D, Thomas L, Goodman S, Aronson R, Jordan J, Kolls B, Dombrowski K, Vinereanu D, Halvorsen S, Berwanger O, Windecker S, Mehran R, Granger C, Alexander J, Lopes R. Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke. JAMA Cardiology 2022, 7: 682-689. PMID: 35612866, PMCID: PMC9134037, DOI: 10.1001/jamacardio.2022.1166.Peer-Reviewed Original ResearchConceptsVitamin K antagonistsAcute coronary syndromePercutaneous coronary interventionAtrial fibrillationTransient ischemic attackCRNM bleedingP2Y12 inhibitorsCoronary syndromeAssociated with numerically lower ratesIschemic eventsCoronary interventionEfficacy of apixabanHAS-BLED scoreNumerically lower ratesOral anticoagulant useRate of bleedingRisk of cerebrovascular ischemic eventsHigher CHA2DS2-VAScCox proportional hazards modelsCerebrovascular ischemic eventsAssociated with lower ratesRandomized clinical trialsProportional hazards modelHAS-BLEDK antagonistsPharmacological Difference Between Platelet Aggregations in Cardioembolic Stroke Patients with Direct Oral Anticoagulants: A Pilot Study
Nakazaki M, Oka S, Magota H, Kiyose R, Onodera R, Ukai R, Kataoka-Sasaki Y, Sasaki M, Honmou O. Pharmacological Difference Between Platelet Aggregations in Cardioembolic Stroke Patients with Direct Oral Anticoagulants: A Pilot Study. Journal Of Stroke And Cerebrovascular Diseases 2022, 31: 106520. PMID: 35523052, DOI: 10.1016/j.jstrokecerebrovasdis.2022.106520.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsPlatelet aggregation testCardioembolic strokePlatelet aggregationFXa inhibitorsOral anticoagulantsStroke patientsPharmacological differencesAdenosine diphosphateAggregation testConcurrent antiplatelet therapyIschemic stroke patientsCardioembolic stroke patientsOnset of symptomsResults Six patientsLight transmission aggregometryFactor Xa inhibitorsAntiplatelet therapySecondary preventionSix patientsAntiplatelet drugsAtrial fibrillationAntiplatelet effectXa inhibitorsDabigatranImpact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial
Welsh R, Dehghani P, Lopes R, Wojdyla D, Aronson R, Granger C, Windecker S, Vora A, Vinereanu D, Halvorsen S, Parkhomenko A, Mehran R, Alexander J, Goodman S. Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial. Open Heart 2022, 9: e001892. PMID: 35172988, PMCID: PMC8852719, DOI: 10.1136/openhrt-2021-001892.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAspirinAtrial FibrillationFactor Xa InhibitorsFemaleHemorrhageHumansIschemiaMaleMedication Therapy ManagementMiddle AgedOutcome and Process Assessment, Health CarePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPreoperative PeriodPyrazolesPyridonesVitamin KConceptsOral anticoagulant useVitamin K antagonistsClinically relevant non-major bleedingAcute coronary syndromePercutaneous coronary interventionNon-major bleedingOral anticoagulantsAtrial fibrillationAUGUSTUS trialOral anticoagulation statusElective percutaneous coronary interventionHAS-BLED scoreRisk of myocardial infarctionSecondary analysisHAS-BLEDK antagonistsOpen-labelHigher CHAPrimary endpointAntithrombotic therapyAnticoagulant useClinical outcomesCoronary syndromeIschaemic eventsRandomised treatment
2021
Contrasting effects of the alkaloid ricinine on the capacity of Anopheles gambiae and Anopheles coluzzii to transmit Plasmodium falciparum
Hien D, Paré P, Cooper A, Koama B, Guissou E, Yaméogo K, Yerbanga R, Farrell I, Ouédraogo J, Gnankiné O, Ignell R, Cohuet A, Dabiré R, Stevenson P, Lefèvre T. Contrasting effects of the alkaloid ricinine on the capacity of Anopheles gambiae and Anopheles coluzzii to transmit Plasmodium falciparum. Parasites & Vectors 2021, 14: 479. PMID: 34526119, PMCID: PMC8444468, DOI: 10.1186/s13071-021-04992-z.Peer-Reviewed Original ResearchConceptsAnopheles coluzziiAnopheles gambiaeCastor bean Ricinus communisSecondary phytochemicalsKey phenotypic traitsNovel control agentsPlant-derived sugarsAbility of mosquitoesPhenotypic traitsPlasmodium falciparumParasite growth ratePlant sugarsPlant nectarFeeding assaysControl agentsMosquito physiologyGrowth rateAnopheles speciesSensu latoAnopheles gambiae sensu latoColuzziiGambiae sensu latoPutative roleP. falciparum infectionMosquito survivalAP-2alpha-mediated activation of E2F and EZH2 drives melanoma metastasis
White J, Thompson D, Koch K, Kiriazov B, Beck A, van der Heide D, Grimm B, Kulak M, Weigel R. AP-2alpha-mediated activation of E2F and EZH2 drives melanoma metastasis. Cancer Research 2021, 81: canres.0772.2021. PMID: 34210752, PMCID: PMC8416798, DOI: 10.1158/0008-5472.can-21-0772.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Protein Complex 2Adaptor Protein Complex alpha SubunitsAnimalsBase SequenceBenzamidesBiomarkersBiphenyl CompoundsCell Line, TumorE2F Transcription FactorsEnhancer of Zeste Homolog 2 ProteinEpigenesis, GeneticHumansMelanocytesMelanomaMiceMice, Inbred NODMice, SCIDMorpholinesNeoplasm MetastasisNeoplasm TransplantationNeoplasms, Second PrimaryPromoter Regions, GeneticPyridonesSingle-Cell AnalysisTranscription Factor AP-2ConceptsAP-2αRepression complexEZH2 inhibitorsAP-2α transcription factorSingle-cell RNA sequencing analysisE2F target genesRNA sequencing analysisSpecific EZH2 inhibitorsAP-2α expressionActivation of E2FAnchorage-independent colony formationMelanocyte stem cellsTumor suppressor activityChromatin marksNucleosome remodelingBioID screenE2F pathwayTranscriptional activationTranscription factorsTarget genesPathway genesAP-2alphaSequencing analysisMelanoma metastasesGenes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply